Please use this identifier to cite or link to this item:
https://ahro.austin.org.au/austinjspui/handle/1/32610| Title: | Clinical Trials in the Brain Tumour Population: Challenges and Strategies for the Future. | Austin Authors: | Gan, Hui Kong ;Day, Bryan W;Harrup, Rosemary;Johns, Terrance G;Lwin, Zarnie;Scott, Andrew Mark;Sim, Hao-Wen;Koh, Eng-Siew | Affiliation: | Olivia Newton-John Cancer Research Institute Sid Faithfull Brain Cancer Laboratory, Cell and Molecular Biology Department, QIMR Berghofer, 300 Herston Rd, Herston, QLD, 4006, Australia.;School of Biomedical Sciences, Queensland University of Technology, Brisbane, QLD, Australia.;Australian Brain Cancer Research Alliance, Melbourne, Australia.;Faculty of Medicine, The University of Queensland, Brisbane, QLD, Australia. Cancer & Blood Services, Royal Hobart Hospital, Hobart, TAS, Australia.;Menzies Research Institute, University of Tasmania, Hobart, TAS, Australia. Australian Brain Cancer Research Alliance, Melbourne, Australia.;Oncogenic Signalling Laboratory, Telethon Kids Institute, Nedlands, WA, Australia. Department of Medical Oncology, Cancer Care Services, Royal Brisbane and Women's Hospital, The University of Queensland, Brisbane, QLD, Australia. Tumour Targeting Program and Centre for Research Excellence in Brain Cancer, Olivia Newton-John Cancer Research Institute, Austin Health, 145 Studley Road, Heidelberg, Melbourne, VIC, 3084, Australia.;La Trobe University School of Cancer Medicine, Heidelberg, VIC, Australia.;Department of Medicine, University of Melbourne, Heidelberg, VIC, Australia.;Australian Brain Cancer Research Alliance, Melbourne, Australia. NHMRC Clinical Trials Centre, Locked Bag 77, Camperdown, NSW, 1450, Australia.;Department of Medical Oncology, Chris O'Brien Lifehouse, Camperdown, NSW, Australia.;Kinghorn Cancer Centre, St Vincent's Hospital Sydney, Darlinghurst, NSW, Australia.;School of Clinical Medicine, Faculty of Medicine and Health, University of New South Wales, Darlinghurst, NSW, Australia. South West Clinical School, Faculty of Medicine, University of New South Wales, Sydney, NSW, Australia.;Department of Radiation Oncology, Liverpool Cancer Therapy Centre, Liverpool, NSW, Australia.;Ingham Institute for Applied Medical Research, Liverpool Hospital, Locked Bag 7103, Liverpool, NSW, Australia. Australian Brain Cancer Research Alliance, Melbourne, Australia. Medicine (University of Melbourne) |
Issue Date: | Jun-2023 | Date: | 2023 | Publication information: | Current Oncology Reports 2023-06; 25(6) | Abstract: | This review identifies challenges and barriers to successful development of drugs in neuro-oncology trials at the preclinical, clinical and translational stages that we believe has contributed to poor outcomes for patients over the last 30 years. Several key strategies have been proposed by leading groups to address these and improve patient outcomes. Better preclinical testing using more sophisticated and clinically relevant models is needed. A greater focus on assessing blood-brain barrier penetrance and targeting key biological processes such as tumour heterogeneity and immune response is vital. Adopting innovative trial designs permitting faster results and addressing key issues (including molecular heterogeneity and combinatorial approaches) is highly desirable. A stronger translational focus is also clearly needed. Implementation of these strategies is already starting to occur. Maintaining and increasing these novel approaches will require coordinated efforts between clinicians, scientists, industry and funding/regulator bodies. | URI: | https://ahro.austin.org.au/austinjspui/handle/1/32610 | DOI: | 10.1007/s11912-023-01394-5 | ORCID: | 0000-0001-7319-8546 |
Journal: | Current Oncology Reports | PubMed URL: | 36976462 | ISSN: | 1534-6269 | Type: | Journal Article | Subjects: | Brain tumour Challenges Innovations Trials |
| Appears in Collections: | Journal articles |
Show full item record
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.